{"filing":{"accession_number":"0001599298-26-000071","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"smmt-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000071/smmt-20260805.htm"},"events":[{"id":24918,"run_id":22591,"accession_number":"0001599298-26-000071","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Summit announced the initiation of HARMONi-GU1, a Phase II/III global clinical trial expanding its ivonescimab development program into urothelial carcinoma (bladder cancer). This represents a material operational and strategic milestone—expansion of the company's clinical pipeline into a new tumor type with planned enrollment of approximately 800 patients and global site activations beginning in Q4 2026. While not a specific named event type (not M\u0026A, not a financial obligation, not a governance change), this is clearly a material operational/strategic development that would affect a reasonable investor's assessment of the company's pipeline progress and future prospects.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25615,"accession_number":"0001599298-26-000071","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Summit announced the initiation of HARMONi-GU1, a Phase II/III global clinical trial expanding its ivonescimab development program into urothelial carcinoma (bladder cancer). This represents a material operational and strategic milestone—expansion of the company's clinical pipeline into a new tumor type with planned enrollment of approximately 800 patients and global site activations beginning in Q4 2026. While not a specific named event type (not M\u0026A, not a financial obligation, not a governance change), this is clearly a material operational/strategic development that would affect a reasonable investor's assessment of the company's pipeline progress and future prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:35:10.382034+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25615,"accession_number":"0001599298-26-000071","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Summit announced the initiation of HARMONi-GU1, a Phase II/III global clinical trial expanding its ivonescimab development program into urothelial carcinoma (bladder cancer). This represents a material operational and strategic milestone—expansion of the company's clinical pipeline into a new tumor type with planned enrollment of approximately 800 patients and global site activations beginning in Q4 2026. While not a specific named event type (not M\u0026A, not a financial obligation, not a governance change), this is clearly a material operational/strategic development that would affect a reasonable investor's assessment of the company's pipeline progress and future prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:35:10.382034+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-08-05"}]}